



PATENT APPLICATION
File No: 00-25

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Darrell C. Conklin, Zeren Gao
Serial No. : 09/819,136
Group Art Unit : 1652
Examiner : Ramirez, D.
Filed : March 27, 2001
For : MULTI-DOMAIN PROTEINASE INHIBITOR
Date Submitted : December 6, 2002

RECEIVED
DEC 18 2002
TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.
The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	10	-25	0	\$9.00	\$000.00
Independent	2	-5	0	\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
				Total	\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker
Registration No. 31,648



#12/C
Dmt
1-9-03

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231.

Dec. 6, 2002

Date

Gary E. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Darrell C. Conklin, Zeren Gao
Serial No. : 09/819,136
Filed : March 27, 2001
For : MULTI-DOMAIN PROTEINASE INHIBITOR

Examiner : Ramirez, Delia M.

Art Unit : 1652

Docket No. : 00-25

Date : December 6, 2002

RECEIVED

DEC 18 2002

TECH CENTER 1600/2900

BOX NON-FEE AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Amendment

Sir:

Please amend the above-identified application as follows:

In the Specification:

Please replace the paragraph at page 25, line 25 through page 26, line 11 with the following amended paragraph:

C1

Cultured mammalian cells are suitable hosts for use within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., *ibid.*), and liposome-mediated transfection (Hawley-Nelson et al., *Focus* 15:73, 1993; Ciccarone et al., *Focus* 15:80, 1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed by, for